T&K: The application for the domestic production drug registration and marketing license of Dydrogesterone Tablets has been accepted
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, T&K announced that its wholly-owned subsidiary Anhui T&K Pharmaceutical Co., Ltd. recently received the "Acceptance Notice" for the domestic production drug registration application for Dienogest Tablets issued by the National Medical Products Administration. Dienogest, as a selective progestin, is used to treat endometriosis, alleviating pain symptoms and stabilizing endometrial tissue, with advantages of good tolerance and low adverse reaction rates
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments